Benchmark Holdings Plc Logo

Benchmark Holdings Plc

Aquaculture biotech providing nutrition and health solutions for sustainable farming.

BMK | IL

Overview

Corporate Details

ISIN(s):
GB00BGHPT808 (+1 more)
LEI:
2138001UQHM4VZGXUJ19
Country:
United Kingdom
Address:
4 PARK SQUARE, THORNCLIFFE PARK, CHAPELTOWN, S35 2PH SHEFFIELD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Benchmark Holdings plc is a leading aquaculture biotechnology company dedicated to driving sustainability in the industry. The company's mission is to provide aquaculture producers with mission-critical products and solutions that enhance farming efficiency, animal health, and welfare. Benchmark's operations are centered around two key divisions: Advanced Nutrition and Health. Its portfolio includes specialized diets, probiotics, vaccines, medicines, and other health products designed to improve productivity and sustainability for its global customer base. By combining biology and technology, Benchmark supports the growth of a sustainable food supply chain.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-18 08:00
Delisting Announcement
Cancellation of Admissions to Trading
English 11.1 KB
2025-08-15 08:00
Delisting Announcement
Last day of trading
English 6.0 KB
2025-08-15 08:00
Delisting Announcement
Benchmark Holdings plc – Last day of trading
English 1.1 KB
2025-08-08 14:06
Delisting Announcement
Update on the cancellation of trading of shares
English 16.2 KB
2025-08-08 14:00
Delisting Announcement
Update on Euronext Oslo Børs approval of the cancellation of the trading of Ben…
English 4.1 KB
2025-08-08 13:55
Delisting Announcement
Benchmark Holdings plc – Decision on date of delisting
English 749 bytes
2025-08-08 13:55
Delisting Announcement
Benchmark Holdings plc – Vedtak om dato for strykning
Norwegian 766 bytes
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 16.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights - Attachment: BMK RNS TVR 31 July.pdf
English 82.3 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 361 bytes
2025-07-25 18:37
Delisting Announcement
Result of Tender Offer - Replacement
English 23.9 KB
2025-07-25 18:30
Declaration of Voting Results & Voting Rights Announcements
Correction: Result of Tender Offer, Total Voting Rights and Directors' Interest…
English 77.2 KB
2025-07-25 18:30
M&A Activity
Correction: Result of Tender Offer, Total Voting Rights and Directors' Interests
English 1.1 KB
2025-07-25 08:00
Share Issue/Capital Change
Result of Tender Offer, Total Voting Rights and Directors' Interests - Attachm…
English 68.6 KB
2025-07-25 08:00
Declaration of Voting Results & Voting Rights Announcements
Result of Tender Offer, Total Voting Rights and Directors' Interests
English 842 bytes

Automate Your Workflow. Get a real-time feed of all Benchmark Holdings Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Benchmark Holdings Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Benchmark Holdings Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS

Talk to a Data Expert

Have a question? We'll get back to you promptly.